Pharmaceutical Research

, Volume 29, Issue 3, pp 837–846

Mesoporous Silicon (PSi) for Sustained Peptide Delivery: Effect of PSi Microparticle Surface Chemistry on Peptide YY3-36 Release

  • Miia Kovalainen
  • Juha Mönkäre
  • Ermei Mäkilä
  • Jarno Salonen
  • Vesa-Pekka Lehto
  • Karl-Heinz Herzig
  • Kristiina Järvinen
Research Paper

DOI: 10.1007/s11095-011-0611-6

Cite this article as:
Kovalainen, M., Mönkäre, J., Mäkilä, E. et al. Pharm Res (2012) 29: 837. doi:10.1007/s11095-011-0611-6



To achieve sustained peptide delivery via mesoporous silicon (PSi) microparticles and to evaluate the effects of different surface chemistries on peptide YY3-36 (PYY3-36) delivery.


PYY3-36 was loaded into thermally oxidized (TOPSi), thermally hydrocarbonized (THCPSi) and undecylenic acid treated THCPSi (UnTHCPSi) microparticles with comparable porous properties. In vitro, PYY3-36 release was investigated by centrifuge. In vivo, PYY3-36 plasma concentrations were analyzed after delivery in microparticles or solution.


Achieved loading degrees were high (12.2 – 16.0% w/w). PYY3-36 release was sustained from all microparticles; order of PYY3-36 release was TOPSi > THCPSi > UnTHCPSi both in vitro and in vivo. In mice, PSi microparticles achieved sustained PYY3-36 release over 4 days, whereas PYY3-36 solution was eliminated in 12 h. In vitro, only 27.7, 14.5 and 6.2% of loaded PYY3-36 was released from TOPSi, THCPSi and UnTHCPSi, respectively. Absolute PYY3-36 bioavailabilities were 98, 13, 9 and 38% when delivered subcutaneously in TOPSi, THCPSi, UnTHCPSi and solution, respectively. The results clearly demonstrate improved bioavailability of PYY3-36 via TOPSi and the importance of surface chemistry of PSi on peptide release.


PSi represents a promising sustained and tailorable release system for PYY3-36.


in vivo mesoporous silicon peptide delivery pharmacokinetics PYY3-36 



porous silicon


thermally hydrocarbonized porous silicon


thermally oxidized porous silicon


undecylenic acid treated thermally hydrocarbonized porous silicon

Supplementary material

11095_2011_611_MOESM1_ESM.tif (8.1 mb)
High Resolution Image (TIFF 8260 kb)
11095_2011_611_MOESM2_ESM.tif (8.7 mb)
High Resolution Image (TIFF 8939 kb)

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Miia Kovalainen
    • 1
  • Juha Mönkäre
    • 1
  • Ermei Mäkilä
    • 2
  • Jarno Salonen
    • 2
  • Vesa-Pekka Lehto
    • 3
  • Karl-Heinz Herzig
    • 4
    • 5
  • Kristiina Järvinen
    • 1
  1. 1.School of Pharmacy, Pharmaceutical Technology, Faculty of Health SciencesUniversity of Eastern FinlandKuopioFinland
  2. 2.Department of Physics and AstronomyUniversity of TurkuTurkuFinland
  3. 3.Faculty of Science and Forestry, Department of Applied PhysicsUniversity of Eastern FinlandKuopioFinland
  4. 4.Institute of Biomedicine, Biocenter of Oulu University of OuluOuluFinland
  5. 5.Department of PsychiatryKuopio University HospitalKuopioFinland

Personalised recommendations